fig3

Figure 3. Schematic representation of 2nd Generation microbiome-based therapeutic approaches: Microbiome-based therapies can be divided into donor-based or donor-independent approaches. Donor-based approaches depend on the need for the donation of fecal material to produce the final therapeutic product. Donor-based approaches require the donation of fecal samples from individuals, which harbor a complex, non-standardized microbial community, and are subject to more intricate regulatory guidelines. On the other hand, LBPs are donor-independent microbiome-based products that consist of a single strain or standardized microbial consortia associated with the gut microbiome that have proven therapeutic effects in clinical trials. LBPs: Live biotherapeutic products.